SAFETY AND EFFICACY FINDINGS OF A PHASE 1B/2 STUDY OF NANATINOSTAT PLUS VALGANCICLOVIR FOR TREATMENT OF RELAPSED/REFRACTORY EPSTEIN-BARR VIRUS-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
a Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil
b Division of Hematology, A Beneficência Portuguesa de São Paulo (BP), São Paulo, Brazil
c Division of Hematology, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HCFMUSP), São Paulo, Brazil
d Division of Hematology, University of Colorado, Denver, United States
e Applied Statistics and Consulting, Spruce Pine, United States
f Viracta Therapeutics, Inc., Cardiff, United States
g Division of Hematologic Malignancies and Hematopoetic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, United States
Read
1072
Timeswas read the article
393
Total PDF
679
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 9 | 4 | 1 | 5 |
| 2025 8 | 31 | 15 | 46 |
| 2025 7 | 45 | 19 | 64 |
| 2025 6 | 32 | 11 | 43 |
| 2025 5 | 48 | 10 | 58 |
| 2025 4 | 44 | 14 | 58 |
| 2025 3 | 51 | 8 | 59 |
| 2025 2 | 33 | 11 | 44 |
| 2025 1 | 24 | 24 | 48 |
| 2024 12 | 19 | 12 | 31 |
| 2024 11 | 25 | 14 | 39 |
| 2024 10 | 34 | 18 | 52 |
| 2024 9 | 42 | 23 | 65 |
| 2024 8 | 34 | 20 | 54 |
| 2024 7 | 38 | 25 | 63 |
| 2024 6 | 32 | 23 | 55 |
| 2024 5 | 37 | 21 | 58 |
| 2024 4 | 36 | 9 | 45 |
| 2024 3 | 22 | 20 | 42 |
| 2024 2 | 14 | 23 | 37 |
| 2024 1 | 14 | 21 | 35 |
| 2023 12 | 12 | 23 | 35 |
| 2023 11 | 6 | 16 | 22 |
| 2023 10 | 2 | 12 | 14 |
Show all
